로그인|회원가입|고객센터|기업교육 문의
페이지 맨 위로 이동
검색

Medical / Drug Development

Alteogen: Monthly Obesity Drug Shows Durability in Animals

Dong-A Ilbo | Updated 2026.11.17
Unveiling Its Proprietary Drug at the Obesity Society (U.S.)
An Alteogen official presenting at the Obesity Society of America (photo provided by the company)
Alteogen’s once-monthly obesity injection under development remained in the body longer in animal trials than the obesity drug candidate of U.S. pharmaceutical company Eli Lilly. The degree of weight regain after discontinuation of dosing was also smaller.

Alteogen announced on the 16th that it had presented these results at ObesityWeek 2026, the annual scientific meeting of the Obesity Society of America, held in Washington, United States. In the experiment, Alteogen’s obesity drug candidate “ALT-M5B4” and Eli Lilly’s next-generation obesity drug candidate “retatrutide” were each administered as a single injection to laboratory animals.

The time required for the drug concentration in the blood to decline by half was 68.1 hours for Alteogen’s candidate, more than four times longer than for retatrutide. In a separate mouse study, the rate of weight regain two weeks after treatment was stopped was 34.7% in mice given Alteogen’s drug and 44.2% in those given Lilly’s drug. Jeon Tae-yeon, CEO of Alteogen, said, “The company will develop an obesity treatment that improves dosing convenience and weight-maintenance effects.”

Jeon Hye-jin

AI-translated with ChatGPT. Provided as is; original Korean text prevails.
Popular News

경영·경제 질문은 AI 비서에게,
무엇이든 물어보세요.

Click!